New antibody-chemo combo offers hope for kids with aggressive nerve cancer

NCT ID NCT07549321

First seen Apr 29, 2026 · Last updated May 07, 2026 · Updated 2 times

Summary

This study tests whether adding an antibody called hu14.18K322A to standard chemotherapy can better shrink or eliminate tumors in children and teens with high-risk neuroblastoma, a rare and aggressive nerve cancer. About 144 participants aged 18 months to under 18 years will receive the combination therapy. The main goals are to see how many patients achieve a complete or partial response and to monitor safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital Colorado Anschutz Medical

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.